NSCLC Stage IV research hub

Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

This study is looking at a new drug called adagrasib for people with a specific type of advanced lung cancer. It focuses on patients who are older (70+) or have poorer health, to see how well the drug works in shrinking their cancer.